Last reviewed · How we verify
Mavyret
At a glance
| Generic name | Mavyret |
|---|---|
| Also known as | Hepatitis C treatment, pibrentasvir, glecaprevir, Zetia |
| Sponsor | Duke University |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Boxed warnings
- WARNING: RISK OF HEPATITIS B VIRUS REACTIVATION IN PATIENTS COINFECTED WITH HCV AND HBV Test all patients for evidence of current or prior hepatitis B virus (HBV) infection before initiating treatment with MAVYRET. HBV reactivation has been reported in HCV/HBV coinfected patients who were undergoing or had completed treatment with HCV direct-acting antivirals and were not receiving HBV antiviral therapy. Some cases have resulted in fulminant hepatitis, hepatic failure, and death. Monitor HCV/HBV
Common side effects
- Headache
- Fatigue
- Nausea
Serious adverse events
- Serious adverse reaction (unspecified)
Key clinical trials
- Study of Glecaprevir/Pibrentasvir to Assess Safety Through Real-World Data
- Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in Women With Hepatitis C With and Without HIV (PHASE1, PHASE2)
- Feasibility and Acceptability of HCV Treatment in Pregnancy
- A Study to Evaluate Preemptive Therapy in Hepatitis C (HCV) Organ Transplant Recipients (PHASE4)
- Rapid HCV Treatment Access for Persons Who Use Drugs (NA)
- A Study of the Safety, Effectiveness and Clinical Use of Maviret in Adolescent Patients With Chronic Hepatitis C Virus
- Glecaprevir/Pibrentasvir for Post-traumatic Stress Disorder (PHASE2, PHASE3)
- Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mavyret CI brief — competitive landscape report
- Mavyret updates RSS · CI watch RSS
- Duke University portfolio CI